2024 - Advancing Alzheimer’s Clinical Trial Endpoints: Imaging Biomarkers, COA Challenges, Movement Measures, and CV Risk

Join this webinar which explores the critical aspects of conducting clinical trials in Alzheimer’s disease (AD) with a focus on innovative methodologies and challenges encountered. The speakers will review the pivotal role of imaging biomarkers in characterizing patient eligibility, ensuring safety and evaluating therapeutic efficacy in AD trials.
Next, the presentation will discuss the evolving landscape and challenges associated with collecting endpoints for clinical outcome assessments (COAs) in a changing patient population. From there the potential of leveraging gait and balance measures for detection and diagnosis of cognitive impairment and dementia and their significance in early intervention will be discussed.
Finally, the speakers will review the complexities of running trials in populations at high risk for cardiovascular (CV) disease, emphasizing the importance of baseline testing regardless of the drug being investigated.
Register for this webinar today to gain insights that can inform sponsors to enhance the design and execution of AD clinical trials.
Keywords: CNS, Commercialization/HEOR/Market Access, Neuroscience Trials, Imaging Biomarkers, Clinical Outcome Assessments, Clinical Trial Endpoints, CNS Trials, Alzheimer's Disease Trials, Clinical Endpoints, COA, Dementia, HEOR, Clinical Data, Biomarkers, CRO, Clinical Research, Cognitive Impairment, Alzheimer's Disease, Alzheimer's